Iovance Biotherapeutics Inc

IOVA
10,85
-0,115 (-1,05%)
14 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202423:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:06EDGAR2Form 8-K - Current report
09/5/202422:01GLOBEIovance Biotherapeutics Reports First Quarter 2024 Financial..
01/5/202412:01GLOBEIovance Biotherapeutics to Host First Quarter 2024 Financial..
30/4/202412:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
24/4/202422:01GLOBEIovance Biotherapeutics to Present Clinical and..
19/4/202423:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
22/3/202422:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
07/3/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202414:00EDGAR2Form 8-K - Current report
04/3/202412:30GLOBEIovance Biotherapeutics Announces FDA has Lifted Clinical..
01/3/202423:00GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
29/2/202413:30EDGAR2Form 8-K - Current report
28/2/202422:05EDGAR2Form 8-K - Current report
28/2/202422:01GLOBEIovance Biotherapeutics Reports Fourth Quarter and Full Year..
22/2/202422:53EDGAR2Form 8-K - Current report
22/2/202414:45GLOBEIovance Biotherapeutics to Host Fourth Quarter and Full-Year..
21/2/202422:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202423:23EDGAR2Form 8-K - Current report
20/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202412:30GLOBEIovance Biotherapeutics, Inc. Announces Pricing of $211..
20/2/202412:03EDGAR2Form 8-K - Current report
16/2/202423:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
16/2/202421:38GLOBEIovance Biotherapeutics to Host Conference Call and Webcast..
16/2/202421:19GLOBEIovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA..
14/2/202412:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202423:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
19/1/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:03EDGAR2Form 8-K - Current report
28/12/202313:27IHMARKETNEWSWall Street Highlights: Amazon to Introduce Ads on Prime..
27/12/202323:00EDGAR2Form 8-K - Current report
27/12/202313:54DJNIovance Shares Fall Premarket As FDA Places Study On Hold..
27/12/202313:00GLOBEIovance Biotherapeutics Announces Clinical Program Update..
22/12/202323:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
17/11/202323:00GLOBEIovance Biotherapeutics Reports Inducement Grants under..
07/11/202323:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:05EDGAR2Form 8-K - Current report
07/11/202322:01GLOBEIovance Biotherapeutics Reports Third Quarter and..
31/10/202321:01GLOBEIovance Biotherapeutics to Host Third Quarter and..
31/10/202314:05GLOBEIovance Biotherapeutics to Present Clinical and Pre-Clinical..
20/10/202323:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
19/10/202302:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 11,21 Min: 10,42 Max: 11,47
Chiusura: 10,965

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network